Headquarters expansion that will quadruple the company's production capacity. Includes a new plant

The first dedicated, fully integrated API and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio. About 1,800 construction jobs and more than 650 new high-paying jobs, including engineers, scientists and lab technicians, will be brought to the Richmond, Virginia region.

Part of a larger, previously announced $27 billion company investment.

A new R&D center at its HQ will create several hundred jobs, reinforcing Amgen’s 45-year presence in the region.

With a manufacturing expansion and modernization in the Research Triangle, Biogen looks to enhance its capabilities for gene-targeted therapies – expanding antisense oligonucleotide production and adding new multi-platform fill-finish capacity at both clinical and commercial scales. Advanced automation and AI-driven process controls are part of the upgrades.

Pledge focus is a new drug substance manufacturing campus in Virginia and expansions of R&D and cell therapy manufacturing elsewhere. 

AstraZeneca will also upgrade its U.S. clinical trial supply network and accelerate development of novel medicines.

Total investment is expected to add tens of thousands of U.S. jobs.

Capability expansion for generic medicine manufacturing and R&D.

Announced plans to build a new biologics manufacturing facility as part of long-term growth strategy. The project is expected to have about a $5 billion economic impact, creating about 300 permanent high-skill jobs and over 500 construction jobs.

Expanding its campus into a major hub for manufacturing continuous glucose monitoring (CGM) systems for diabetes management and adding a new diagnostics production facility. 

The expansion is expected to create “hundreds” of skilled manufacturing jobs and thousands of construction jobs in Indiana.